ClinicalTrials.gg
CompletedNCT04599998Updated May 16, 2024

Long-term Follow-up Findings of Inpatients for COVID-19 Pneumonia

An observational study in Covid19, sponsored by Koc University Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Koc University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
28
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in COVID-19 with a site in Turkey — 9 open to participants now, 11 under way, 3 of them phase 3. COVID-19 · Turkey.

Enrollment
231st of 251
28 · median 148
Started
2020
with 166 others
Observational
251 of 429
2 open now
Registered
86th of 429
by date

Among the 429 studies in COVID-19 with a site in Turkey, this one is the 231st largest by enrollment of the 251 observational ones that give a count, is one of 167 that started in 2020, is one of 251 observational ones, and was the 86th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

9 of the 429 studies in COVID-19 with a site in Turkey are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in COVID-19 with a site in Turkey, or all of them as a file.
02

Study summary

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus (SARS-CoV-2) that can progress to severe multiorgan disease requiring hospitalization. The medium and long-term impact in survivors of COVID-19 on lung function, imaging by thoracic CT, exercise capacity, and health-related quality of life and the relation of these parameters remains to be determined.

Read the detailed description

Aim: To evaluate medium to late (visit 1: 6-12 months after hospital discharge) effects of COVID-19 on lung function, exercise capacity, thoracic CT findings, symptoms and HRQoL in patients with confirmed diagnosis of SARS-CoV-2 infection and the relation between these parameters.

Material and methods: Prospective cohort of subjects with laboratory and/or thoracic CT confirmed COVID-19 who were treated as inpatients. Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT) and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.

The minimum sample size was estimated as 37 participants.

03

Conditions studied

  • Covid19

Browse trials for

Keywords

  • Covid19
  • lung functions
  • cardiopulmonary exercise testing
  • thoracic CT
  • 6 minute walking test
  • Short form 36 questionnaire
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults with Covid-19 diagnosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with Covid 19 diagnosis
  • Ability to read and speak
  • Signed .
  • Able to perform exercise testing and walking

Exclusion criteria

Exclusion Criteria:

  • Subjects with limited exercise capacity
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
28 participants (actual)
Patient registry
No

Groups and cohorts

  • COVID-19 inpatients

    Patients with laboratory and/or thoracic CT confirmed COVID-19 pneumonia ; older than18 years of age; treated as inpatients; evaluated at 6-12 months after hospital discharge in outpatient clinic

    Diagnostic Test: spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire

Interventions

  • Diagnostic testspirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire

    Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.

06

What researchers measure

Primary outcomes

  1. Forced vital capacity (FVC)

    in ml

    Time frame: at 6-12 months after discharge

  2. Lung diffusion capacity for carbon monoxide (DLCO)

    DLCO (%predicted); DLCO/alveolar volume- DLCO/VA (%predicted)

    Time frame: at 6-12 months after discharge

  3. 6-minute walk test distance

    m

    Time frame: at 6-12 months after discharge

  4. Short-form 36 questionnaire (SF-36)

    scores range between 0 and 100 with higher scores indicating a better HRQoL

    Time frame: at 6-12 months after discharge

  5. Oxygen uptake at peak exercise

    from incremental Cardiopulmonary exercise test (% of predicted)

    Time frame: at 6-12 months after discharge

  6. Minute-ventilation/carbon dioxide output during exercise

    from incremental Cardiopulmonary exercise test (L/L)

    Time frame: at 6-12 months after discharge

  7. Dyspnea during exercise

    from incremental Cardiopulmonary exercise test (measured with 10-point categorical Borg scale

    Time frame: at 6-12 months after discharge

  8. Thoracic CT findings

    lung parenchymal abnormalities as percentage of occupied lung

    Time frame: in the first week of pneumonia and at 6-12 months after discharge

  9. Forced expiratory volume in 1 second

    in ml and %predicted

    Time frame: at 6-12 months after discharge

  10. FEV1/FVC ratio

    in %

    Time frame: at 6-12 months after discharge

  11. Forced vital capacity %predicted (FVC%)

    in %

    Time frame: at 6-12 months after discharge

Secondary outcomes

  1. Signs and symptoms

    Recorded separately as present or absent) mortality (recorded as present or absent)

    Time frame: in the first week of pneumonia and at 6-12 months after discharge

  2. Time to hospital discharge

    in days

    Time frame: in hospital

  3. ICU discharge

    in days

    Time frame: in hospital

  4. Weaning from intubation

    in days

    Time frame: in the period of intensive care

  5. Weaning from supplemental oxygen

    in days

    Time frame: in hospital

  6. Weaning from noninvasive mechanical ventilation

    in days

    Time frame: in hospital

  7. Mortality

    recorded as present or absent

    Time frame: in hospital and at 6-12 months after discharge

07

Study locations

1 site
  • Koç University Hospital
    Istanbul, 34010, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Feb 2022, 16 months.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 16 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2020
First posted
Oct 23, 2020
StartActual
Oct 15, 2020
Primary completionActual
Feb 15, 2022
CompletionActual
Mar 1, 2023
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04599998
Lead sponsor
Koc University Hospital
Responsible party
Fatma Işıl Uzel (MD, Koc University Hospital) — Principal investigator
First posted
Oct 23, 2020
Start date
Oct 15, 2020
Primary completion
Feb 15, 2022
Completion
Mar 1, 2023
Last update
May 16, 2024

Study contacts

Benan Çağlayan, Prof Dr
study chair · Koç University Hospital Pulmonology Department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion